|
C17ORF85 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.10650000062896E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.74969999999774E-06 |
| Normal-vs-Stage2 |
2.02440000000026E-05 |
| Normal-vs-Stage3 |
6.74350020268832E-10 |
| Normal-vs-Stage4 |
7.71720021219835E-10 |
| Stage1-vs-Stage2 |
5.988800E-01 |
| Stage1-vs-Stage3 |
2.281600E-02 |
| Stage1-vs-Stage4 |
6.341600E-03 |
| Stage2-vs-Stage3 |
2.608000E-01 |
| Stage2-vs-Stage4 |
1.252170E-01 |
| Stage3-vs-Stage4 |
5.871000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.77470000309421E-08 |
| Normal-vs-AfricanAmerican |
4.365000E-03 |
| Normal-vs-Asian |
1.162240E-04 |
| Caucasian-vs-AfricanAmerican |
4.715800E-01 |
| Caucasian-vs-Asian |
6.027000E-01 |
| AfricanAmerican-vs-Asian |
7.701200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.15759998756226E-09 |
| Normal-vs-Female |
6.21579999693367E-08 |
| Male-vs-Female |
3.007600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.10799999994715E-06 |
| Normal-vs-Age(41-60Yrs) |
7.66240000338314E-08 |
| Normal-vs-Age(61-80Yrs) |
4.26639945594331E-10 |
| Normal-vs-Age(81-100Yrs) |
2.001800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.052980E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.753890E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.515800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.575400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.267200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.589200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.820630E-04 |
| Classical-VS-Follicular |
3.944500E-02 |
| Classical-VS-Other |
5.714400E-01 |
| Classical-VS-Normal |
8.42539999990066E-07 |
| Tall-VS-Follicular |
1.270020E-01 |
| Tall-VS-Other |
4.673200E-01 |
| Tall-VS-Normal |
3.4662994696788E-10 |
| Follicular-VS-Other |
8.594600E-01 |
| Follicular-VS-Normal |
2.73990000021485E-07 |
| Other-VS-Normal |
1.972190E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.5546000042832E-08 |
| Normal-vs-N1 |
1.52908999999646E-05 |
| N0-vs-N1 |
8.790800E-01 |
|
|
